CAPR — Capricor Therapeutics Share News
0.000.00%
Last trade - 00:00- $356.39m
- $118.46m
Capricor Therapeutics Q2 net loss widens on higher expenses
Capricor Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Capricor Therapeutics, Inc. expected to post a loss of 59 cents a share - Earnings Preview
Health Rounds: Experimental drug helps advanced cancer patients avoid bladder removal surgery
Health Rounds: Cell therapy that may slow heart failure progression in Duchenne muscular dystrophy hits FDA roadblock (updated)
Health Rounds: Experimental cell therapy slows heart failure progression in Duchenne muscular dystrophy
U.S. STOCKS ON THE MOVE-Mastercard, Yum, Equinix
Capricor hits 2-yr low after FDA panel votes against Duchenne therapy
U.S. STOCKS ON THE MOVE-Mastercard, Starbucks, Meta
Capricor plummets after FDA panel votes against Duchenne heart disease therapy (updated)
U.S. STOCKS ON THE MOVE-Avery Dennison, Huntington Ingalls, XPO
Capricor plummets after FDA panel votes against Duchenne heart disease therapy
Capricor tanks after FDA panel votes against Duchenne therapy
Street View: Capricor in 'precarious position' as approval in doubt
NASDAQ RESUMED AT 07:10 AM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
U.S. RESEARCH ROUNDUP-Equinix, Meta, S&P Global
FDA panel votes against Capricor's Duchenne heart disease therapy (updated)
FDA advisers vote against Capricor's Duchenne heart disease therapy